The impact of biomarkers of malignancy (IMWG SLiM criteria) in myeloma in a real‐world population: Clinical characteristics, therapy and outcomes from the Australian and New Zealand Myeloma and Related Diseases Registry (ANZ MRDR)

Documenti analoghi

• Autologous stem cell transplantation for multiple myeloma patients whose myeloma‐defining event was SLiM
  di: Iuliana Vaxman, et al.
  Pubblicazione: (2024)
• No benefit from daratumumab, bortezomib and dexamethasone (D‐Vd) in real‐world patients with functional high‐risk multiple myeloma: A report from the Myeloma and Related Diseases Registry
  di: Sueh‐li Lim, et al.
  Pubblicazione: (2025)
• Longitudinal Changes in Transfusion Practice in Myelodysplastic Syndromes: A Population Data‐Linkage Study
  di: Allison Mo, et al.
  Pubblicazione: (2026)
• Management of relapsed multiple myeloma: A British Society of Haematology and UK Myeloma Society guideline
  di: Matthew Jenner, et al.
  Pubblicazione: (2025)
• Cytogenetic abnormalities in multiple myeloma patients according to age: A real‐world study by the Nordic Myeloma Study Group
  di: Sigrún Thorsteinsdóttir, et al.
  Pubblicazione: (2025)